| Literature DB >> 35448671 |
Hanna Kronfeld1, Nicole Kemper2, Christina S Hölzel1.
Abstract
Clostridium perfringens (C. perfringens) forms part of the intestinal microbiome, but is also a known pathogen in histotoxic infections. The significance of the pathogen as a cause of uterine infections in cattle has been little studied so far. Here, we analyzed the association between a pathological puerperium in cattle and the detection of C. perfringens in a prospective longitudinal study. Clostridium perfringens were only found in vaginal and uterine samples of diseased cattle, and were absent in healthy controls. Isolates (n = 21) were tested for the production of major toxins (alpha-, beta-, epsilon-toxin) by ELISA and for the potential of production of major (alpha-, beta-, iota-toxin) and minor toxins (beta2 toxin) by PCR. Furthermore, antimicrobial susceptibility was also tested phenotypically by microdilution. Despite the frequent use of tetracycline treatment in cows suffering from puerperal disorders, no isolate showed phenotypic tetracycline resistance. Most isolates did not release major amounts of toxin. The strict association of C. perfringens with puerperal disease, together with the absence of major toxins might hint towards a major role of other or unknown clostridial virulence factors in uterine disease.Entities:
Keywords: Clostridium perfringens; dairy cows; metritis; puerperium; uterine infection
Year: 2022 PMID: 35448671 PMCID: PMC9030417 DOI: 10.3390/vetsci9040173
Source DB: PubMed Journal: Vet Sci ISSN: 2306-7381
Classification of C. perfringens into five toxin types and the associated major toxins; + = major toxin present; − = major toxin not present, as described by Markey et al. [1].
|
| Major Toxin | |||
|---|---|---|---|---|
| type | α | β | ε | ι |
| A | + | − | − | − |
| B | + | + | (+) | − |
| C | + | + | − | − |
| D | + | − | + | − |
| E | + | − | − | + |
α = alpha-toxin, β = beta-toxin, ε = epsilon-toxin, ι = iota-toxin.
Oligonucleotide primers for C. perfringens toxin gene detection.
| Toxin/Gene | Primer | Oligonucleotide Sequence | Reference |
|---|---|---|---|
| alpha/ | CPALPHATOX-L | 5′-AAGATTTGTAAGGCGCTT-3′ | Buogo et al. [ |
| beta/ | CPBETATOX-L | 5′-AGGAGGTTTTTTTATGAAG-3′ | Buogo et al. [ |
| iota/ | CPIOTA-L | 5′-AATGCCATATCAAAAAATAA-3′ | Braun et al. [ |
| beta2/ | P319BETA2 | 5′-GAAAGGTAATGGAGAATTATCTTAATGC-3′ | Herholz et al. [ |
Distribution of C. perfringens- positive diseased cows with respect to the disease patterns shown during puerperium. Numbers add up to more than 14, since some cows had more than one diagnosis.
| Diagnosis | % |
|
|---|---|---|
| Retained fetal membranes | 50.0 | 7 |
| Puerperal metritis | 21.4 | 3 |
| Grade 1 | 14.3 | 2 |
| Grade 2 | 7.1 | 1 |
| Clinical metritis | 92.9 | 13 |
| Clinical endometritis | 85.7 | 12 |
| Urovagina | 7.1 | 1 |
Overview of the incidence of C. perfringens positive cows over the sampling period and localization.
| Cows with a Pathological Puerperium (of Total 46) | Isolates | ||
|---|---|---|---|
| % |
|
| |
| 58.7 | 27 | ||
| 51.9 | 14 | 21 | |
| localization of | % |
| |
| vagina | 14.3 | 2 | 8 |
| uterus | 50.0 | 7 | 13 |
| vagina and uterus | 35.7 | 5 | / a |
| time of sampling | % |
| |
| 2 | 78.6 | 11 # * | 15 |
| 4 | 21.4 | 3 # | 3 # |
| 6 | 21.4 | 3 | 3 |
| 14 | 0 | 0 | 0 |
# = 3 cows were positive on day 2 and 4 p.p.; fishers exact test: * p < 0.007. a = the five cases where cows were positive both in the uterus and the vagina resulted in 6 isolates from the vagina and 6 isolates from the uterus. These isolates are included in the respective lines for vagina and uterus.
Figure 1Visualization of the distribution of C. perfringens isolates (n = 21) among the hosts (n = 14) in relation to the time of sampling and the localization; each symbol stands for an isolate, different symbols symbolize the cows, different colors symbolize the localization; black = vagina, blue = uterus, line = follow-up isolate.
Minimum inhibitory concentration (MIC) range, MIC50, MIC90, CLSI- breakpoint values (mg/L) and prevalence (%) of antibiotic resistance in 21 C. perfringens isolates.
| Antibiotics | MIC Range | MIC50 | MIC90 | CLSI-Breakpoints | Number of Resistant Isolates | Percentage of Resistant Isolates |
|---|---|---|---|---|---|---|
|
| ||||||
| Penicillin G | 0.0625–8 | ≤0.0625 | 0.125 | S ≤ 0.5; R ≥ 2 | 2/21 | 9.5 |
| Ampicillin | 0.0625–8 | ≤0.0625 | ≤0.0625 | S ≤ 0.5; R ≥ 2 | 1/21 | 4.8 |
| Amoxicillin/Clavulanate | 0.5/0.25–64/32 | ≤0.5/0.25 | ≤0.5/0.25 | S ≤ 4/2; R ≥ 16/8 | 0/21 | 0 |
| Piperacillin/Tazobactam | 1/4–64/4 | ≤1/4 | ≤1/4 | S ≤ 16/4; R ≥ 128/4 | 0/21 | 0 |
|
| ||||||
| Meropenem | 0.5–64 | ≤0.5 | ≤0.5 | S ≤ 4; R ≥ 16 | 0/21 | 0 |
| Imipenem | 0.5–64 | ≤0.5 | ≤0.5 | S ≤ 4; R ≥ 16 | 0/21 | 0 |
| Ertapenem | 0.125–16 | ≤0.125 | ≤0.125 | S ≤ 4; R ≥ 16 | 0/21 | 0 |
|
| ||||||
| Metronidazole | 0.25–32 | 1 | 2 | S ≤ 8; R ≥ 32 | 1/21 | 4.8 |
|
| ||||||
| Moxifloxacine | 0.0625–8 | 0.5 | 0.5 | S ≤ 2; R ≥ 8 | 0/21 | 0 |
|
| ||||||
| Clindamycine | 0.0625–8 | 0.5 | 2.0 | S ≤ 2; R ≥ 8 | 2/21 | 9.5 |
|
| ||||||
| Doxycycline | 0.125–16 | 1 | 2 | S ≤ 4; R ≥ 16 | 0/21 | 0 |
| Tigecycline | 1–8 | ≤1 | ≤1 | S ≤ 4; R ≥ 16 | 0/21 | 0 |
|
| ||||||
| Vancomycin | 2.0–8.0 | ≤2.0 | ≤2.0 | S ≤ 2; R ≥ 4 * | 0/21 | 0 |
S = susceptible, R = resistant; * = EUCAST breakpoint (version 11.0; January 2021); bold = antibiotic classes.
Overview of the phenotypic reaction profile of C. perfringens isolates to selected antibiotics.
| Antibiotics | Number of | |||
|---|---|---|---|---|
| 1 a | 1 #, a | 1 b | 18 ##, c | |
| Penicillin G | R | R | S | S |
| Ampicillin | R | I | S | S |
| Amoxicillin/Clavulanate | S | S | S | S |
| Piperacillin/Tazobactam | S | S | S | S |
| Meropenem | S | S | S | S |
| Imipenem | S | S | S | S |
| Ertapenem | S | S | S | S |
| Metronidazole | S | S | R | S |
| Moxifloxacine | S | S | S | S |
| Clindamycine | R | R | S | S |
| Doxycycline | S | S | S | S |
| Tigecycline | S | S | S | S |
| Vancomycin i | S | S | S | S |
i = here, evaluation was carried out via the breakpoint according to EUCAST (status: January 2021); R = resistant (highlighted in orange), I = intermediate (highlighted in yellow); S = susceptible; # = day 4 p.p., ## = day 4 p.p. (n = 2) and day 6 p.p. (n = 3), all other isolates were collected on day 2 p.p.; a = treated with benzylpenicillin procaine, b = treated with benzylpenicillin procaine, tetracycline hydrochloride and penethamathydroiodid (due to additional mastitis), c = 14 isolates from treated cows and 4 isolates from untreated cows, underlined: follow-up isolate from day 2 to day 4 p.p.
Figure 2Sum of antimicrobial resistances compared among the sampling dates, C. perfringens isolates n = 3 (day 2 n = 2; day 4 n = 1) from two antibiotic- treated cows; PEN = penicillin, AMP = ampicillin, MTR = metronidazole, CLI = clindamycine; a = on day 2 and day 4 p.p., one isolate each could be detected from the same animal, b = AMP on day 4 intermediate; one cow was treated with benzylpenicillin procaine, the other cow additionally with tetracycline hydrochloride and Penethamathydroiodid (due to additional mastitis), treatment start for both cows: day of calving.
Profiles of the accompanying findings of the C. perfringens positive cows (n = 14) with potential uterine pathogens.
| Bacterial Concomitant Findings | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||
|
| ||||||||||||